首頁
AMPAC Fine Chemicals

11月 2025AMPAC Fine Chemicals的市場佔有率分析

As a leading global CDMO, SK pharmteco provides drug development and manufacturing services for small molecule, biologic, cell and gene therapies.

健康 > 生物技術和製藥

域名ampacfinechemicals.com

成立年份1998

僱員501 - 1000

年度營收$100M - $200M

AMPAC Fine Chemicals

AMPAC Fine Chemicals（包含公司地區）

ampacfinechemicals.com

查看更多網站流量與參與度資訊

AMPAC Fine Chemicals截至 11月 2025 的總收入為 100M - 200M

AMPAC Fine Chemicals 熱門網域產生的總收入

AMPAC Fine Chemicals 熱門網域 3 年內的總收入

AMPAC Fine Chemicals 熱門網域的總收入

ampacfinechemicals.com100M - 200M

透過銷售情報查看更多內容

AMPAC Fine Chemicals的熱門網域總造訪量

了解AMPAC Fine Chemicals市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

無可顯示數據

AMPAC Fine Chemicals的熱門網域平均造訪時長

分析AMPAC Fine Chemicals參與度指標。

過去 3 個月平均造訪時長

無可顯示數據

AMPAC Fine Chemicals的熱門網域平均頁面瀏覽量

了解AMPAC Fine Chemicals如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

無可顯示數據

AMPAC Fine Chemicals按網域劃分的熱門競爭對手

11月 2025的熱門類似網站，依相似度排名

skpharmteco.com公司名SK Pharmteco Inc.僱員1001 - 5000總部美國, 加利福尼亞, Rancho Cordova年度營收$500M - $1B訪問總量10.4K健康 > 生物技術和製藥

使用的熱門技術AMPAC Fine Chemicals

这些是AMPAC Fine Chemicals顶级域名使用的行业网站技术

小工具 (7)

reCAPTCHA

付費廣告 (3)

DoubleClick

內容管理系統 (3)

WordPress

行動裝置 (2)

Meta Viewport

更多技術

8

檢視所有

新聞與訊號來自AMPAC Fine Chemicals

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Ampacfinechemicals sold assets to SK pharmteco Inc. in the amount of $576M on Jan 1st '18.SK Pharmteco has operated the facility since it acquired it from Ampac Fine Chemicals in 2018 for around 800 billion won ($576 million).

新聞Ampacfinechemicals is developing COVID drugs.In Petersburg, Phlow is partnering with nonprofit generic drugmaker Civica Rx and California-based AMPAC Fine Chemicals to produce COVID drugs as part of a federal initiative to create the domestic supply chain for critical pharmaceuticals and ingredients.

新聞Ampacfinechemicals is developing COVID drugs.In Petersburg, Phlow is partnering with nonprofit generic drug-maker Civica Rx and California-based AMPAC Fine Chemicals to produce COVID drugs as part of a federal initiative to create the domestic supply chain for critical pharmaceuticals and ingredients.